Momenta Phamaceuticals, Inc. (MNTA) Misses Q4 FFO by 7c
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 FFO of $0.20, $0.07 worse than the analyst estimate of $0.27.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Innovaro (INV) Misses Q2 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
